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A B S T R A C T
Background: Huntington’s disease (HD) is a fatal genetic neurodegenerative disorder with no effective treatment
currently available. Progressive basal ganglia and whole-brain atrophy and concurrent cognitive deterioration
are prototypical aspects of HD. However, the specific patterns of brain atrophy underlying cognitive impairment
of different severity in HD are poorly understood. The aim of this study was to investigate the specific structural
brain correlates of major cognitive deficits in HD and to explore its association with neuropsychological in-
dicators.
Participants: Thirty-five symptomatic early-to-mild HD patients and 15 healthy controls (HC) with available T1-
MRI imaging were included in this study.
Methods: In this cross-sectional study, HD patients were classified as patients with (HD-Dem) and without (HD-
ND) major cognitive impairment in the range of dementia. This classification was based on previously validated
PD-CRS cutoff scores for HD. Differences in brain atrophy across groups were studied by means of grey-matter
volume voxel-based morphometry (GMV-VBM) and cortical thickness (Cth). Voxelwise and vertexwise general
linear models were used to assess the group comparisons, controlling for the effects of age, sex, education, CAG
repeat length and severity of motor symptoms. Clusters surviving p < 0.05 and family-wise error (FWE) cor-
rection were considered statistically significant. In order to characterize the impact on cognitive performance of
the observed brain differences across groups, GMV and Cth values in the set of significant regions were computed
and correlated with specific neuropsychological tests.
Results: All groups had similar sociodemographic profiles, and the HD groups did not significantly differ in terms
of CAG repeat length. Compared to HC, both HD groups exhibited significant atrophy in multiple subcortical and
parietal brain regions. However, compared to HC and HD-ND groups, HD-Dem patients showed a more pro-
minent pattern of reduced GMV and cortical thinning. Importantly, this thinning was restricted to regions of the
parietal-temporal and occipital cortices. Furthermore, these brain alterations were further associated with
poorer cognitive performance in tasks assessing frontal-executive and attention domains as well as memory,
language and constructional abilities.
Conclusions: Major cognitive impairment in the range of dementia in HD is associated with brain and cognitive
alterations exceeding the prototypical frontal-executive deficits commonly recognized in HD. The observed
posterior-cortical damage identified by MRI and its association with memory, language, and visuoconstructive
dysfunction suggest a strong involvement of extra-striatal atrophy in the onset of severe cognitive dysfunction in
HD patients. Critically, major cognitive impairment in this sample was not associated with CAG repeat length,
age or education. This finding could support a possible involvement of additional neuropathological mechanisms
aggravating cognitive deterioration in HD.
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Huntington’s disease (HD) is a monogenic, autosomal dominant,
neurodegenerative disease caused by the an abnormal CAG expansion
on the HTT gene (Walker, 2007). Its inevitably progressive course is
characterized by progressive motor abnormalities and neuropsychiatric
symptoms, early cognitive deterioration, and the development of de-
mentia (Ross et al., 2014; Peavy et al., 2010).
The key neuropathological hallmark of HD is progressive atrophy of
the basal ganglia, which may be detected up to 15 years before motor
symptoms appear and the diagnosis is made. Compelling evidence,
however, shows that HD affects not only basal ganglia but the whole-
brain(Rosas et al., 2008). Cross-sectional and longitudinal studies have
illustrated that even in the premanifest stage of the disease, grey matter
volume (GMV) reductions, cortical thinning (Cth), and reduced brain
metabolism affect multiple extra-striatal regions. These regions com-
prise extensive territories of the parietal, temporal and occipital lobes
that also contribute to the clinical expression of the disease(Rosas et al.,
2008, 2005; Nopoulos et al., 2010; Tabrizi et al., 2009; Coppen et al.,
2018; Rub et al., 2015; Kuwert et al., 1990).
From a neurocognitive perspective, HD has been described as a
prototypical frontal-subcortical dementia due to striatal, but also tha-
lamic degeneration(Kassubek et al., 2005), with frontal-executive dis-
turbances, attention deficits, and processing speed reduction as the
most consistently affected cognitive domains(Snowden, 2017). In-
volvement of the caudate nucleus and putamen in cognitive aspects of
HD is characteristic(Tabrizi et al., 2009; Dogan et al., 2013). However,
many studies in HD have shown that as the neuropathological changes
extend to multiple extra-striatal regions, cognitive domains other than
frontal-executive functions become affected. These include alterations
in visuomotor integration(Gomez-Anson et al., 2009; Say et al., 2011),
episodic and autobiographical memory(Carmichael et al., 2019; Harris
et al., 2019), visual perception(Martinez-Horta et al., 2019; Coppen
et al., 2019), mental rotation(Wolf et al., 2014; Labuschagne et al.,
2016) and language production and organization(Hinzen et al., 2018;
Chan et al., 2019; Chenery et al., 2002; Podoll et al., 1988), suggesting
that the cognitive phenotype of HD cannot be attributed solely to
frontal-striatal dysfunction.
Longitudinal studies have demonstrated that CAG repeat length
plays a key role in the linear decline of cognitive capacity throughout
disease progression(Tabrizi et al., 2012; Paulsen et al., 2014;
Consortium, 2015; Langbehn et al., 2019). However, age-at-onset
(AAO) and the rate of progression of cognitive deterioration varies
greatly among individuals even when age, education level and CAG
repeat length are equivalent(Consortium, 2015; Braisch et al., 2019).
This heterogeneity suggests that, besides CAG repeat length, other
mechanisms such as environmental and genetic variables also con-
tribute to the neuropathological and clinical progression of cognitive
deterioration in HD. It has recently been shown, for example, that ge-
netic variability in chromosome 15, contributes to age at onset of motor
and cognitive symptoms (Consortium, 2015). Other mechanisms, such
as MAPT haplotypes and their role in the expression of TAU, have also
been associated with cognitive progression in HD (Vuono et al., 2015).
Studies addressing the mechanisms involved in the differential ex-
pression of cognitive deterioration in HD are scarce, probably due to the
lack of specific diagnostic criteria to differentiate HD patients with mild
cognitive impairment from those with severe or major cognitive im-
pairment in the range of dementia, and even from those with normal
cognition (Mestre et al., 2018). The specific patterns of brain alterations
underlying major cognitive impairment in HD thus remain elusive,
partly because of the difficulty in appropriately grouping patients ac-
cording to cognitive status. To overcome this limitation, we recently
validated the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS) as
a screening tool for global cognition in HD(Martinez-Horta et al., 2020).
We showed that the HD-specific PD-CRS cutoff scores have a good ca-
pacity to discriminate between categories of cognitive status in patients
with HD. Although this approach may have limitations, it distinguishes
patients with normal or mild global cognitive defects from those with
severe cognitive impairment in the range of dementia.
In the present study, our main aim was to explore specific structural
brain differences underlying major cognitive impairment in the range of




We included thirty-five symptomatic gene-mutation carriers with
CAG repeat length > 38 regularly attending the outpatient HD-Clinic
of the Movement Disorders Unit at Hospital de la Santa Creu i Sant Pau
in Barcelona, and fifteen age- and education-matched healthy controls
(HC). HC were non-consanguineous relatives of the HD participants.
None of the HCs had a history of neurologic, psychiatric or un-
compensated systemic diseases. Similarly, all HD participants were free
of any neurological disorder other than HD and had no history of brain
surgery, traumatic brain injury, epilepsy, drug abuse, or un-
compensated systemic disease.
Written informed consent was obtained from all participants and all
procedures were performed in accordance with the standards of the
Ethics Committee at Hospital de la Santa Creu i Sant Pau in Barcelona
and in accordance with the 1964 Declaration of Helsinki and its later
amendments.
2.2. Assessments
HD patients were classified as with severe or without severe cog-
nitive impairment using the HD-specific PD-CRS cutoff scores(Martinez-
Horta et al., 2020). These cutoff scores were determined in HD popu-
lation in a previous study using as gold standard the presence of major
cognitive and functional impairment. Thus, in accordance with this
previous study we used the PD-CRS total score ≤ 64 to classify patients
as with major cognitive impairment in the range of dementia(Martinez-
Horta et al., 2020). This instrument assesses nine subtests: immediate
and delayed verbal memory, confrontation naming, attention, working
memory, unprompted draw of a clock, copy of a clock, alternating
verbal fluency, and action verbal fluency. The total score is computed
by summing all the raw scores obtained in each subtest, but specific
scores can be grouped to compute a “frontal-subcortical” score and a
“posterior-cortical” score(Pagonabarraga et al., 2008). In the present
study, the PD-CRS total score was used to group patients according to
their cognitive status. Accordingly, patients who obtained a PD-CRS
total score > 64 were included in the “non-demented” group (HD-ND)
whereas patients who obtained a PD-CRS total score ≤ 64 were con-
sidered as with major cognitive impairment in the range of dementia
(HD-Dem). The non-demented group included a slight proportion of
participants with mild cognitive deficits whereas in the demented group
all participants exhibited severe cognitive deficits. Accordingly, this
approach allowed us to compare participants with severe cognitive
impairment vs those with minor or absent cognitive impairment ac-
cording to the PD-CRS. Additionally, we administered the Mini-Mental
State Examination (MMSE) screening test for comparative analyses with
the classification done with the PD-CRS.
We also administered the composite cognitive score of the Unified
Huntington’s Disease Rating Scale (UHDRS cogscore) and other mea-
sures commonly used in cognitive assessment protocols in HD
(Landwehrmeyer et al., 2017). Accordingly, assessments included the
Symbol Digit Modalities Test (SDMT), the phonetic fluency test with
letters F, A and S, the Stroop color-naming, word-reading and inter-
ference tests, the semantic fluency test (animals) and parts A and B of
the Trail Making Test (TMT). Raw scores for all these measures were
adjusted for age and education level and then converted to z-scores. A
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global composite z-score was also calculated combining all these mea-
sures.
Screening for global cognitive status was also performed in all HC
using the PD-CRS and the MMSE. In this group, all participants ob-
tained a PD-CRS > 81 (mean = 106.7 ± 10.7) and a MMSE > 27
(mean = 29.3 ± 0.8), indicating absence of cognitive impairment.
For the HD participants, a neurologist specialized in HD (JPP) rated
the severity of motor symptoms using the Unified Huntington’s Disease
Rating Scale – Total motor score (UHDRS-TMS)(Hs, 1996). All HD
participants obtained a diagnostic confidence level = 4, indicating that
motor abnormalities were unequivocal signs of HD with a confidence
level of 99%. All HD patients were classified as having early stage or
mild disease according to a total functional capacity score
(TFC) > 6(Shoulson and Fahn, 1979). The disease burden score (DBS),
an index assumed to reflect lifelong exposure to mutant huntingtin, was
calculated using the following formula based on age and CAG repeat
length: DBS = age × (CAG-35.5)(Penney et al., 1997). We also re-
corded socio-demographic and clinical data, including age, sex, edu-
cation and global cognitive functioning.
2.3. Neuroimaging acquisition and preprocessing
Volumetric MRI was available for all participants. 3D-T1 images
were acquired on a 3 T Philips Achieva using an MP-RAGE sequence
(TR/TE = 6.74/3.14 ms, flip-angle = 8°, field of view = 23 cm, ma-
trix = 256x256 and slice thickness = 1 mm).
We applied voxel-based morphometry (VBM) and cortical thickness
(Cth) neuroimaging preprocessing procedures. A standard VBM pipe-
line using the Statistical Parametrical Mapping software package
(SPM12, http://www.fil.ion.ucl.ac.uk/spm) was performed(Martinez-
Horta et al., 2019). Briefly, GMV tissue probability maps were com-
puted from T1-MRI scans. These maps were then normalized to the
Montreal Neurological Institute (MNI) space by applying the DARTEL
algorithm. The resulting normalized GMV maps were then smoothed
using an isotropic spatial filter of 8x8x8mm full-width at half-maximum
(FWHM) to reduce inter-individual variability.
Cth analysis was performed using the FreeSurfer 6.0 software
package (https://surfer.nmr.mgh.harvard.edu). The specific methods
used for cortical reconstruction of T1-MRI brain images have been fully
described elsewhere(Fischl and Dale, 2000). In short, optimized surface
deformation models following intensity gradients accurately identify
white matter and gray matter boundaries in the cerebral cortex, from
which cortical thickness is computed at each vertex of the resulting
surface. The resulting cortical surfaces are normalized to average space
and smoothed using a Gaussian kernel of 15 mm FWHM.
2.4. Statistical analysis
Socio-demographic and clinical variables were subjected to ANOVA
between the three groups. Post-hoc independent t-test comparisons
were performed between the three groups for continuous variables and
χ2 for categorical variables. To calculate the effect size of the differ-
ences observed between cognitive groups we used Cohen’s d coefficient
(d values: 0–0.2, small effect size; 0.6, moderate effect size; ≥ 0.8, large
effect size).
Voxelwise and vertexwise measures derived from VBM and Cth
analyses were introduced into a generalized lineal model (GLM) to
compare these measures across groups, using age, sex, education, CAG
repeat length and UHDRS-TMS as covariates. The following pairwise
group comparisons were performed: HC > HD-ND, HC > HD-Dem,
and HD-ND > HD-Dem. The set of clusters surviving p < 0.05 and
family-wise error (FWE) correction for multiple-comparison (cluster-
level Bonferroni correction for VBM and Monte-Carlo simulation with
10,000 repeats for Cth) were considered statistically significant.
To investigate the clinical translation of the imaging findings, we
computed quantitative volumetric and mean Cth information at the
identified clusters where we observed significant differences across
groups. Using linear regression analysis, we then studied the association
of these imaging measures with the different cognitive variables within
an exploratory analysis, controlling again for the effect of potential
confounders such as age, education, CAG repeat length and UHDRS-
TMS, for which a p-value < 0.05 was considered significant.
3. Results
3.1. Clinical and sociodemographic data
The sample consisted of 35 HD patients (mean age = 51.8 ± 12;
mean CAG = 43.7 ± 2.8; mean years of education = 11.5 ± 4.5;
mean TFC = 11.2 ± 2) and 15 HC (mean age = 45.8 ± 8; mean
years of education = 12.3 ± 1.6). According to the PD-CRS score,
n = 20 were included in the HD-ND group (mean PD-CRS total
score = 84.3 ± 15; mean age = 50.8 ± 11; mean CAG = 43.3 ± 3)
and n = 15 in the HD-Dem group (mean PD-CRS total score = 51.2 ±
10; mean age = 53.2 ± 14; mean CAG= 44 ± 3). As summarized in
table 1, no significant differences were found between HC, HD-ND and
HD-Dem groups regarding age and education. In the HD groups, no
significant differences were found between HD-ND and HD-Dem re-
garding age, gender, education, CAG repeat length or DBS, but the HD-
Dem group showed a significantly higher UHDRS-TMS, lower TFC,
lower UHDRS cogscore, lower PD-CRS total score, and lower MMSE
score. In the HD-ND group, the mean MMSE score was 27.85 ± 1.8 (no
impairment) while in the HD-Dem group it was 21.6 ± 2.6 (below the
Table 1
Clinical and Sociodemographic characteristics of the sample.
Controls HD HD-ND HD-Dem P
Age 45.9 ± 8 51.8 ± 12 50.85 ± 11 53.2 ± 14 a0.096; b0.156; c0.102; d0.590
Gender (f/m) 4/11 23/12 12/8 11/4 a0.012; b0.052; c0.013; d0.324
Education 12.3 ± 2 11.5 ± 4 11.2 ± 5 12 ± 4 a0.376; b0.346; c0.778; d0.615
CAG – 43.7 ± 3 43.3 ± 3 44 ± 3 d0.424
DBS1 – 492 ± 84 469 ± 80 523 ± 83 d0.061
UHDRS-TMS2 – 28.5 ± 17 22.5 ± 18 37.2 ± 11 d < 0.01
TFC3 – 11.2 ± 2 12.1 ± 1 10 ± 2 d < 0.01
PD-CRS total score 106.7 ± 10.7 70.17 ± 21 84.3 ± 15 51.2 ± 10 a < 0.001; b < 0.001; c < 0.001; d < 0.001
UHDRS cogscore – 170.2 ± 78 212 ± 72 114 ± 47 d < 0.001
MMSE 29.3 ± 0.8 25.2 ± 3.8 27.8 ± 1.8 21.6 ± 2.6 a < 0.001; b<0.005; c < 0.001; d < 0.001
1 Disease burden score; 2Unified Huntington’s disease rating scale – Total motor score; 3Total functional capacity.
a HC vs HD
b HC vs HD-ND
c HC vs HD-Dem
d HD-ND vs HD-Dem
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general < 24 cutoff for dementia).
3.2. Neuropsychological performance in HD groups
The HD-ND group obtained a mean PD-CRS total score of
84.3 ± 15 which, according to PD-CRS criteria, situates this group in
the range between cognitive normality and mild cognitive deficits.
Looking at the prevalence of cases scoring above the proposed cutoff
score for mild cognitive impairment in the HD-ND group (PD-
CRS ≤ 81), we saw that 45% of the patients scored for mild cognitive
impairment while 55% scored for cognitive normality. None of the
defects, however, were severe enough to fulfill the criteria for dementia
per specific PD-CRS criteria in HD.
As reported in table 2, after adjustment for age and education, all
the measures obtained through the UHDRS cogscore and through the
other Enroll-HD assessments were significantly different between
groups in all the cases with the exception of the phonetic verbal flu-
ency. In the HD-ND group, all the obtained z-scores were in the lower
range of normality, but above the critical cutoff of −1.5 SD with the
exception of the phonetic verbal fluency (-1.6 ± 0.9). In this group the
mean composite z-score was −1.2 ± 0.9 with 35% of cases scoring
below −1.5 SD. Conversely, in the HD-Dem group all measures scored
below −2 SD and the mean composite z-score was −2.3 ± 0.7 with
73.3% of cases scoring below −1.5 SD. In congruence with the range of
PD-CRS scores obtained by the HD-ND group, performance below −1.5
SD was found in more than half of the non-demented cases for the
Stroop color-naming, Stroop word-reading, Stroop interference, and for
the phonetic verbal fluency (FAS). In the HD-Dem group, performance
below −1.5 SD was found in>80% of cases in most of the tasks
Table 3.
Group comparisons between HD-ND and HD-Dem groups showed
that HD-Dem scores were significantly lower on all the cognitive tests.
We found a large effect size in all groups according to d Cohen’s coef-
ficient > 0.8.
3.3. GMV differences between groups
The voxelwise group comparison revealed significant GMV differ-
ences when comparing the HD-ND and HD-Dem groups with the HC
group, and also when comparing the HD-ND group with the HD-Dem
group. Specifically, compared to the HC group, HD-ND showed sig-
nificantly lower GMV in large cortico-subcortical clusters. The set of
significant clusters included the bilateral caudate nucleus and putamen,
the bilateral insula, the bilateral inferior orbital prefrontal cortex
(oPFC), and also the right rolandic operculum, the right mid-occipital
gyrus, the right superior parietal gyrus, and the right mid-frontal and
mid- and superior oPFC. Comparing HC and HD-Dem, we found marked
GMV differences bilaterally in the whole basal ganglia and in the in-
sular cortex, in the left superior and medial frontal cortex, and in sev-
eral posterior-cortical clusters, including the right superior and inferior
occipital gyrus and the right lingual gyrus.
When we compared the HD-ND and HD-Dem group, the latter
showed significantly reduced GMV in parietal-temporal regions, speci-
fically in the bilateral anterior and posterior insular cortex, the superior
temporal gyrus, and the left supramarginal gyrus (Fig. 1).
Table 2
Performance in neuropsychological measures.
HD-ND HD-Dem P d
PD-CRS Total 84.3 ± 16 51.2 ± 10 <0.001 1.543
PD-CRS frontal-subcortical 57.2 ± 14 28.9 ± 7 <0.001 1.560
PD-CRS posterior-cortical 27.1 ± 3 22.2 ± 6 <0.005 0.993
Immediate verbal memory 8.1 ± 1 5.5 ± 2 <0.001 1.168
Naming 17.6 ± 2 14.5 ± 4 <0.005 0.946
Sustained attention 6.7 ± 2 2.2 ± 2 <0.001 1.418
Working memory 5.1 ± 1 3 ± 2 <0.005 1.084
Clock drawing 8.3 ± 2 6.2 ± 3 <0.01 0.866
Clock copying 9.4 ± 1 7.6 ± 2 <0.005 0.957
Delayed verbal memory 6.2 ± 2 3.3 ± 2 <0.001 1.203
Alternating verbal fluency 9.6 ± 5 3.7 ± 2 <0.001 1.202
Action verbal fluency 12.9 ± 6 5.5 ± 1 <0.001 1.251
SDMT 31.8 ± 15 15.9 ± 6 <0.001 1.391
Z-score −1.1 ± 1.3 −2.2 ± 1 <0.05 1.039
% cases Z-score < -1.5 SD 35% 66.7% χ2 = 0.65
Stroop color-naming 51.2 ± 16 28.2 ± 12 <0.001 1.626
Z-score −1.3 ± 1.1 −2.6 ± 0.5 < 0.001 1.272
% cases Z-score < -1.5 SD 55% 93.3% χ2 < 0.05
Stroop word-reading 76.6 ± 25 41.3 ± 20 <0.001 1.559
Z-score −1.3 ± 1.3 −2.4 ± 0.8 < 0.01 1.143
% cases Z-score < -1.5 SD 50% 80% χ2 = 0.07
Stroop interference 28 ± 11 14.5 ± 8 <0.001 1.493
Z-score −1.3 ± 1 −2.2 ± 0.7 < 0.005 0.948
% cases Z-score < -1.5 SD 50% 80% χ2 = 0.07
FAS 24.2 ± 13 14.5 ± 11 <0.05 0.805
Z-score −1.6 ± 0.9 −2.1 ± 1 0.116 0.561
% cases Z-score < -1.5 SD 60% 80% χ2 = 0.18
Semantic fluency 14.8 ± 4 9 ± 3 <0.001 1.640
Z-score −1.3 ± 0.8 −2.3 ± 0.5 < 0.005 0.994
% cases Z-score < -1.5 SD 30% 80% χ2 < 0.005
TMT-A 57.2 ± 32 118.8 ± 62 <0.005 1.248
Z-score −0.7 ± 1.4 −2.1 ± 1 <0.005 1.416
% cases Z-score < -1.5 SD 0% 100% χ2 < 0.001
TMT-B 149.6 ± 80 221.8 ± 34 <0.01 1.174
Z-score −1 ± 1.5 −2.3 ± 0.8 < 0.01 1.250
% cases Z-score < -1.5 SD 40% 80% χ2 = 0.05
Composite Z-score −1.2 ± 0.9 −2.3 ± 0.7 < 0.005 1.078
% cases Z-score < -1.5 SD 35% 73.3% χ2 = 0.05
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3.4. Cth differences between groups
The vertexwise comparison between HC and HD-ND groups showed
a pattern of cortical thinning bilaterally in multiple fronto-temporal and
parieto-occipital regions in the HD-ND group. These regions were the
rostral mid-frontal and superior frontal gyrus, the orbital PFC, the su-
perior temporal gyrus, the supramarginal, inferior and superior parietal
gyrus, the lateral occipital gyrus, the precuneus, the precentral gyrus,
and the pars triangularis. Compared to the HC group, the HD-Dem
group showed a similar but more significant thinning pattern than that
in the HD-ND group. Differences were also found in the post-central
gyrus, the inferior and the mid-temporal gyrus, and the fusiform gyrus.
Comparing the HD-ND and HD-Dem groups we found that the HD-
Dem group was characterized by a pattern of cortical thinning
predominantly affecting fronto-temporal and parietal regions of the left
hemisphere and temporo-occipital regions of the right hemisphere. In
the left hemisphere, significant differences involved the inferior tem-
poral and the fusiform gyrus, the supramarginal and inferior parietal
gyrus, the precentral and postcentral gyrus, the caudal and rostral mid-
frontal gyrus, the insula, the pars triangularis, and the rostral middle
frontal gyrus. Conversely, in the right hemisphere, differences were
eminently circumscribed to the temporal pole, the superior and inferior
temporal gyrus, the fusiform gyrus and the lateral occipital gyrus
(Fig. 2).
3.5. Cognitive-imaging regression analysis:
Linear regression analysis showed that after adjusting for age,
education, CAG repeat length and UHDRS-TMS, GMV at multiple
clusters obtained in the VBM analysis contributed strongly to global
cognitive performance. PD-CRS total score performance was strongly
associated with GMV in the basal ganglia (β = 0.456; P = 0.017), the
frontal lobes (β = 0.586; P = 0.005), the temporal lobes (β = 0.587;
P = 0.004), the insular cortex (β = 0.621; P = 0.002), the mid cin-
gulate (β = 0.431; P = 0.036), and the occipital lobe (β = 0.441;
P = 0.043). PD-CRS performance was also associated with GMV in the
parietal lobe (β = 0.373; P = 0.043). However, this association was
also influenced by the UHDRS-TMS (β = -0.390; P = 0.038) (Fig. 3).
Following the same linear regression analysis approach, we looked
at specific clusters of GMV and their association with PD-CRS total
score and performance in each subtest as well as with performance in
all the other cognitive measures administered. Given the high number
of correlation analyses performed between each cluster and each PD-
CRS subtest, these results are reported in supplementary data. The PD-
CRS total score was associated with GMV in the left (β = 0.491;
P = 0.013) and right putamen (β = 0.556; P = 0.006), with the left
(β = 0.523; P = 0.011) and right inferior oPFC (β = 0.531;
P = 0.009), with the left (β = 0.602; P = 0.003) and right insular
cortex (β = 0.632; P = 0.002), with the left (β = 0.666; P = 0.001)
and right superior temporal gyrus (β = 0.495; P = 0.011), with the left
(β = 0.563; P = 0.009) and right inferior temporal gyrus (β = 0.548;
P = 0.010), with the right cuneus (β = 0.508; P = 0.019), with the left
mid oPFC (β = 0.515; P = 0.020), with the right mid-temporal pole
(β = 0.473; P = 0.014), with the left (β = 0.648; P = 0.002) and right
mid-frontal gyrus (β = 0.579; P = 0.007), with the left (β = 0.591;
P = 0.003) and right-mid temporal gyrus (β = 0.567; P = 0.006), with
the right inferior parietal lobe (β = 0.482; P = 0.007), with the right
rectus gyrus (β = 0.573; P = 0.006), with the right superior oPFC
(β = 0.501; P = 0.019), and with the left (β = 0.520; P = 0.013 and
right medial superior PFC (β = 0.545; P = 0.011).
Focusing in the other cognitive measures, we observed that SDMT
Table 3
Cluster description table of the VBM-GMV analyses.
MNI coordinates (x, y,
z)
Cluster size T value
HD-ND > HD-Dem
Right insula 48–8 5 2298 5.22




Left superior temporal gyrus −56–6 −2 2568 4.31
Left supramarginal gyrus −45–26 24 4.10
Left posterior insula −36–23 23 4.82
HC > HD-ND
Left insula −31 9 10 6473 7
Left inferior oPFC −41 38–9 6.33
Left caudate/putamen −12 3 20 6.13
Right insula 31 14 8 6871 6.17
Right caudate/putamen 9 14–1 6.15
Right rolandic operculum 36–15 20 5.75
Right inferior oPFC 30 30–8 5.69
Right mid-occipital 36–68 26 1115 5.15
Right parietal superior 26–69 51 4.23
Right mid-frontal 33 59 15 1330 4.84
Right superior oPFC 29 51–3 4.54




−20 14 6 37,308 8.18
Right superior occipital 21–90 17 3970 6.21
Right lingual gyrus 17–86 −11 6
Right inferior occipital gyrus 30–87 −6 5.81
Right precentral gyrus 45 0 35 857 5.18
Left frontal superior medial −6 24 42 2957 4.89
SMA −9 21 51 4.02
Left superior frontal −17 44 38 4.77
FWE corrected (p < 0.05)
Fig. 1. Regions showing lower GMV (A) and lower Cth (B) in the HD-ND and in the HD-Dem groups compared to the HC group. No regions showed a significant
increase in grey matter volume. For depicting purposes, the image is shown at p < 0.001.
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performance correlated with GMV in the left mid-temporal gyrus
(β = 0.515; P < 0.005), the left superior temporal gyrus (β = 0.409;
P < 0.05) and the inferior frontal gyrus (β = 0.450; P < 0.05).
Semantic fluency correlated strongly with GMV in the right insular
cortex (β = 0.493; P < 0.01), the left superior temporal gyrus
(β = 0.500; P < 0.01), the right inferior temporal gyrus (β = 0.489;
P < 0.01), the bilateral mid-temporal pole (β = 0.522; P < 0.005),
and the right mid-frontal gyrus (β = 0.463; P < 0.05).
In the Cth analyses, multiple regions overlapping the VBM-GMV
findings were strongly associated with cognitive performance by means
of the PD-CRS total score. The most significant clusters were found at
the level of posterior-cortical regions, specifically at the fusiform gyrus
in the temporo-occipital region (β = 0.491; P = 0.008). The PD-CRS
posterior-cortical score was associated with cortical thickness in the
right lateral occipital (β = 0.392; P < 0.05) and in the right fusiform
gyrus (β = 0.512; P < 0.01). Focusing on PD-CRS subtests, immediate
verbal memory was associated with the left inferior temporal cortex
(β = 0.435; P < 0.05). Confrontation naming (β = 0.465; P < 0.05),
sustained attention, and (β = 0.396; P < 0.05), and action verbal
fluency (β = 0.446; P < 0.05) where associated with the right fusi-
form gyrus. Working memory was also associated with the left supra-
marginal gyrus (β = 0.535; P < 0.005), and the left fusiform gyrus
(β = 0.541; P < 0.005). Focusing on the cogscore and related mea-
sures, total cogscore was not associated with Cth. The Stroop color-
naming was associated with the superior temporal gyrus (β = 0.395;
P < 0.05), and with the right lateral occipital gyrus (β = 0.449;
P < 0.05), and the semantic verbal fluency was associated with the
right fusiform gyrus (β = 0.407; P < 0.05).
4. Discussion:
In the present study, major cognitive impairment in the range of
Fig. 2. Regions showing lower GMV (A) and lower Cth (B) in the HD-Dem group than in the HD-ND group. No regions showed a significant increase in grey matter
volume. For depicting purposes, the image is shown at p < 0.005.
Fig. 3. Linear regression analysis depicting correlations between GMV/Cth clusters and PD-CRS total score.
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dementia -as determined using the specific PD-CRS cutoff scores for HD-
is associated with brain and cognitive differences that exceed the pro-
totypical pattern of frontal-executive, attention and processing speed
deficits attributed to frontal-striatal atrophy, and critically involve
more severe atrophy of posterior-cortical brain regions.
Our results highlight that severe cognitive impairment in the range
of dementia may occur in the early stages of HD and with relative in-
dependence of the CAG repeat length, DBS, age and education. Notably,
this more severe form of cognitive impairment is associated with a
widespread pattern of cortical thinning and whole-brain atrophy that
involves multiple cortical and subcortical clusters. The imaging data,
highlights that, as previously reported, GMV atrophy is mostly ascribed
to the basal ganglia, frontal and occipital lobe, and Cth involves the
temporal and parieto-occipital regions(Rosas et al., 2008, 2005; Tabrizi
et al., 2009). Importantly, group comparisons showed that a more
prominent decrease of GMV and Cth is present in those participants
exhibiting severe cognitive deterioration even when controlling for the
effect of age, CAG, education of UHDRS-TMS. Accordingly, more ad-
vanced disease stage or higher DBS cannot explain these differences.
Our findings are in accordance with previous works showing that
the development of cognitive deterioration in HD cannot be solely at-
tributed to basal ganglia atrophy(Rosas et al., 2008; Nopoulos et al.,
2010; Tabrizi et al., 2009; Coppen et al., 2018; Podoll et al., 1988; Say
et al., 2011; Carmichael et al., 2019; Harris et al., 2019; Martinez-Horta
et al., 2019; Wolf et al., 2014; Labuschagne et al., 2016; Hinzen et al.,
2018; Chan et al., 2019). Structures of the basal ganglia, such as the
caudate nucleus and putamen, but also the insular cortex, the PFC and
the occipital and parietal cortex, strongly differentiated non-demented
HD patients from healthy controls. However, the most representative
brain changes differentiating patients with major cognitive impairment
from non-demented HD patients were found at the level of parieto-
temporal regions, including, bilaterally, the anterior and posterior in-
sular cortex, the superior temporal gyrus, and the left supramarginal
gyrus. In terms of cortical thinning, our results pointed in the same
direction, supporting the critical participation of decreased cortical
thinning in fronto-temporal and parietal regions of the left hemisphere
and in temporo-occipital regions of the right hemisphere in the more
severe forms of cognitive deterioration in HD.
The involvement of cortical atrophy in HD, especially in parietal
and occipital regions, is a well-known finding supported by several
imaging studies(Rosas et al., 2008, 2005; Kuwert et al., 1990; Tabrizi
et al., 2009; Coppen et al., 2018). However, the functional translation
of these cortical changes is partially understood. In this sense, our data
supports for the first time that more aggressive cortical atrophy is, at
least, critically associated with the presentation of a significantly more
sever profile of multi-domain cognitive and functional affectation in
HD.
As expected, both the measures of GMV and cortical thinning cor-
related with multiple cognitive variables. However, among the various
measures obtained for cognitive performance, those focusing on ex-
ecutive functions, memory, processing speed, language and construc-
tional abilities were those better characterizing patients with dementia.
These data suggest that the neurocognitive profile differs between HD
patients with and those without major cognitive impairment in the
range of dementia according to the PD-CRS classification. Whereas HD
patients with normal-to-mild cognitive deficits exhibit a prototypical
frontal-executive dysfunction profile, HD patients with major cognitive
impairment exhibit a cortical-subcortical profile with deficits extending
beyond executive functions and involving amnestic difficulties, con-
structional apraxia, confrontation naming deficits and reduced se-
mantic abilities. However, these findings emerged performing com-
parisons with the subtests comprising the PD-CRS, it is, the instrument
used to classify patients. Thus, further studies should explore the spe-
cific neuropsychological correlates of major cognitive impairment and
related brain differences in HD using additional comprehensive neu-
ropsychological assessment.
Previous studies have highlighted the participation of extra-striatal
GMV atrophy and cortical thinning in the clinical expression of HD
(Rosas et al., 2008, 2005; Nopoulos et al., 2010; Tabrizi et al., 2009).
When addressing cognitive aspects, these previous studies focused on
specific measures of verbal fluency and psychomotor processing speed
but not on multiple measures of global cognitive performance. Al-
though they performed correlational analysis between brain structure
and cognitive performance, they did not compared patients according
to the severity of cognitive deterioration. Nevertheless, cortical thick-
ness of the pre-central gyrus, the superior temporal gyrus, the superior
frontal gyrus, the lingual gyrus, the precuneus and the cuneus were
found to be associated with verbal fluency performance. Cortical
thickness of the pre-central gyrus, the bilateral paracentral lobule and
the occipital cortex were also associated with psychomotor processing
speed(Rosas et al., 2008; Nopoulos et al., 2010). Regarding the impact
of cortical changes over functional capacity, the most significant asso-
ciations were found between TFC and the motor cortex, the superior
parietal, and the cuneus(Rosas et al., 2008). Similarly, other studies
highlighted the involvement of multiple areas related to executive
functions and sensorimotor and visuospatial processing in cognitive
performance in HD(Garcia-Gorro et al., 2019). Interestingly, more re-
cent data also point to hippocampal-dependent memory deficits in HD
that cannot be solely explained as a function of degeneration in the
basal ganglia(Carmichael et al., 2019; Harris et al., 2019).
Keeping in mind that the two HD groups were matched for age,
gender, education, CAG and disease burden and that healthy controls
were also matched in terms of age, and education, our findings suggest
that mechanisms other than only those promoted as a function of CAG
repeat length, DBS, age or education level contribute to a differential
course and expression of cognitive deterioration in HD. Although mu-
tant huntingtin aggregation is the primary mechanism leading to HD
(Langbehn et al., 2019; Penney et al., 1997; Wild et al., 2015), multiple
mechanisms are also known to participate in the neuropathology of HD
(Rub et al., 2016). However, how these additional mechanisms con-
tribute to variability in the phenotypic expression of HD is not fully
elucidated. Of these mechanisms, inflammatory, autoimmune activity
and TAU pathology have been suggested to play a cardinal role in
neurodegeneration and clinical expression of HD(Rocha et al., 2016).
The question regarding the possible participation of these mechanisms
in the acceleration of cognitive deterioration and related neurodegen-
eration in HD is only partially understood. TAU pathology and the re-
lated MAPT H2 haplotype have been associated with the rate of cog-
nitive decline in HD(Vuono et al., 2015; Fernandez-Nogales et al.,
2014). Whether these mechanisms contribute to the extent of brain
differences observed in our sample is as yet unknown. In this sense,
further studies must clarify the role of TAU pathology and other me-
chanisms on neurodegeneration and related cognitive deficits in HD.
Moreover, how and when these mechanisms start promoting clinical
and brain changes and why they affect people with equivalent CAG and
DBS in a different manner merits further in-depth research. In any case,
the present study adds novel evidence on the heterogeneity of HD, and
supports the need identifying mechanisms participating in this clinical
heterogeneity. This is of major importance taking into account that
ongoing and imminent clinical trials on HD are focused on huntingtin-
lowering strategies but did not take into account other potential factors
contributing to disease severity(Tabrizi et al., 2019).
In any case, pinpointing the pattern of brain changes and the cog-
nitive profile of major cognitive impairment in the range of dementia in
HD has valuable implications that merit further research in bigger
samples and in a longitudinal design.
The main limitation of the present study is the lack of a gold-stan-
dard to classify patients according to cognitive status, but the method
we used to classify patients has recently been shown to be reliable in
this population(Martinez-Horta et al., 2020). Despite this limitation, it
is reasonable to assume that the measure we used for classification
differentiates patients with normal cognitive function or mild cognitive
S. Martinez-Horta, et al. NeuroImage: Clinical 28 (2020) 102415
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defects from those with severe cognitive alterations. However, the
concept of dementia used in the present work must be taken cautiously
because of the absence of HD-specific clinical diagnostic criteria for
dementia. Moreover, the use of a functional assessment other than the
TFC, specifically addressing cognitive-related functional deficits, must
be considered in further studies. Other obvious limitations to take in
consideration are the small sample size and the cross-sectional design of
the study. Accordingly, will be required to confirm our findings in
further studies addressing this question in a bigger sample and in a
longitudinal setting.
5. Conclusions
Overall, significant patterns of cortical thinning and reduced GMV
in parieto-temporal and occipital regions are associated with more se-
vere cognitive deterioration in HD. The addition of cortical-instru-
mental, semantic and amnestic-like deficits to the prototypical frontal-
executive neurocognitive profile of HD is a differentiating characteristic
of major cognitive impairment in the range of dementia in HD. Early
detection of brain changes and cognitive parameters associated with
severe forms of cognitive deterioration in HD may contribute to the
early identification of individuals at greater risk of a more rapid and
aggressive course of cognitive impairment. Identifying the mechanisms
that contribute to this more aggressive cognitive deterioration should
be of major relevance in the planning of future clinical trials.
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